MOSCOW, April 13. /TASS/. Johnson & Johnson has postponed the use of its vaccine in European countries following reports about the jab’s possible connection to the formation of blood clots, the company said in a press release on Tuesday.
The company notes that the decision was made after the recommendation of American regulators to suspend the use of the drug in the United States due to the possible side effects that the vaccine can cause. In particular six cases of formation of blood clots post-vaccination were registered in the country.
"We have been reviewing these cases with European health authorities. We have made the decision to proactively delay the rollout of our vaccine in Europe," the company said. It noted that only six cases of the possible adverse effect had been reported so far out of more than 6.8 mln doses administered.
Earlier on Tuesday, the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA) of the Department of Health and Human Services recommended suspending the use of the vaccine against coronavirus by Johnson & Johnson due to possible side effects after inoculation.
Earlier, it was reported that the European Medicines Agency was studying possible thromboembolic complications in some patients who received a vaccine against coronavirus developed by Janssen, a subdivision of J&J. To date, four cases of such complications have been recorded, with one of them occurring during clinical trials and three - during vaccination in the US. One of them resulted in a fatal outcome.